Form 4: Precision BioSciences Director Boosts Stake
Insider Transaction Report
Precision BioSciences Inc. Director Stanley Frankel acquired 2,700 shares of common stock at $4.97 per share.
Summary
- Stanley Frankel, a Director of Precision BioSciences Inc. (DTIL), acquired 2,700 shares of the company's common stock.
- The transaction occurred on September 26, 2025, at a price of $4.97 per share.
- Following this acquisition, Mr. Frankel beneficially owns a total of 16,778 shares of common stock.
- The transaction was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
Sentiment
Score: 7
Explanation: The sentiment is positive due to a director increasing their stake in the company, which typically signals confidence in the company's future performance.
Positives
- Director Stanley Frankel increased his beneficial ownership in Precision BioSciences Inc. by acquiring 2,700 shares, signaling confidence in the company's future prospects.
- The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned and structured approach to insider trading.
Future Outlook
The filing does not contain any explicit forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
Insider buying, particularly by a director, can be viewed as a positive signal within the biotechnology industry, suggesting management's belief in the company's long-term potential, especially given the inherent risks and long development cycles in the sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan | The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | 09/26/2025 | Indicates a pre-arranged trading plan, which is a standard governance practice for insiders to avoid accusations of trading on material non-public information. |
Stakeholder Impact
- Shareholders may view the director's increased ownership as a positive indicator of management alignment with shareholder interests and confidence in the company's value.
Key Dates
| Date | Description |
|---|---|
| 09/26/2025 | Date of common stock acquisition by Director Stanley Frankel. |
| 09/30/2025 | Date the Form 4 filing was signed. |
Recommendation
buyA director's decision to purchase additional shares, especially under a Rule 10b5-1 plan, often signals strong insider confidence in the company's future prospects and current valuation. This insider buying can be a positive indicator for investors, suggesting potential upside.
Keywords
Precision BioSciences, DTIL, Insider Buying, Director Purchase, Stock Acquisition, Form 4, Biotechnology, Gene Editing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.